Novartis Teams Up With Legend, Moving CAR-T Into Solid Tumors

The Swiss drug maker is licensing multiple DLL3-targeting CAR-Ts from the Chinese biotech, including one already in early clinical development, and will use its T-Charge manufacturing platform.